112
Views
19
CrossRef citations to date
0
Altmetric
Original Research

Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study

, , &
Pages 449-456 | Published online: 24 Apr 2013

References

  • AscherBZakineBKestemontPBaspeyrasMBougaraASantiniJA multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar linesJ Am Acad Dermatol200451222323315280841
  • CarruthersACarruthersJProspective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytidsDermatol Surg200531101297130316188182
  • CarruthersACarruthersJSaidSDose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in femalesDermatol Surg200531441442215871316
  • CarruthersJALoweNJMenterMAA multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Am Acad Dermatol200246684084912063480
  • MonheitGCarruthersABrandtFRandRA randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal doseDermatol Surg2007331 SpecS51S5917241415
  • SattlerGCallanderMGrablowitzDNoninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown linesDermatol Surg201036S42146215421134045
  • ImhofMKühneUA phase III study of incobotulinumtoxinA in the treatment of glabellar frown linesJ Clin Aesthet Dermatol2011410283422010053
  • CarruthersACarruthersJColemanWPIIIMulticentre, randomized, Phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown linesDermatol Surg2013
  • HankeWNarinsRSBrandtFA randomized, placebo-controlled, double blind Phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpointDermatol Surg2013
  • Bocouture® [package insert] Summary of product characteristicsFrankfurtMerz Pharmaceuticals2010
  • BlitzerABinderWJAvivJEKeenMSBrinMFThe management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patientsArch Otolaryngol Head Neck Surg199712343893929109785
  • BeerKRBoydCPatelRKBowenBJamesSPBrinMFRapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar linesJ Drugs Dermatol2011101394421197522
  • SchlessingerJMonheitGKaneMAMendelsohnNTime to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type ADermatol Surg201137101434144221745254
  • FlynnTCCarruthersACarruthersJValidated assessment scales for the upper faceDermatol Surg2012382 Spec30931922316187
  • JostWHKohlABrinkmannSComesGEfficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteersJ Neural Transm2005112790591315526142
  • RapplTWiednerMKranzlbinderBHaasFIs there a difference in persistence, efficiency and efficacy of 3 BoNT/A-containing products? A double-blind, randomised studyPresented at the 4th International Master Course on Aging SkinHong Kong, China2010 Jul 10–12 Hong Kong, China
  • FlynnTCBotulinum toxin: examining duration of effect in facial aesthetic applicationsAm J Clin Dermatol201011318319920369902
  • RzanyBFlynnTCSchlöbeAHeinzMHarringtonLLong-term results for incobotulinumtoxinA in the treatment of glabellar frown linesDermatol Surg2013399510323190342
  • PragerWWissmüllerEKollhorstBWilliamsSZschockeIComparison of two botulinum toxin type A preparations for treating crow’s feet: a split-face, double-blind, proof-of-concept studyDermatol Surg201036Suppl 42155216021134046
  • CarruthersACarruthersJA single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacyJ Am Acad Dermatol200960697297919467368